This protocol describes the reprogramming of primary amniotic fluid and membrane mesenchymal stem cells into induced pluripotent stem cells using a non-integrating episomal approach in fully chemically defined conditions. Procedures of extraction, culture, reprogramming, and characterization of the resulting induced pluripotent stem cells by stringent methods are detailed.
Autologous cell-based therapies got a step closer to reality with the introduction of induced pluripotent stem cells. Fetal stem cells, such as amniotic fluid and membrane mesenchymal stem cells, represent a unique type of undifferentiated cells with promise in tissue engineering and for reprogramming into iPSC for future pediatric interventions and stem cell banking. The protocol presented here describes an optimized procedure for extracting and culturing primary amniotic fluid and membrane mesenchymal stem cells and generating episomal induced pluripotent stem cells from these cells in fully chemically defined culture conditions utilizing human recombinant vitronectin and the E8 medium. Characterization of the new lines by applying stringent methods – flow cytometry, confocal imaging, teratoma formation and transcriptional profiling – is also described. The newly generated lines express markers of embryonic stem cells – Oct3/4A, Nanog, Sox2, TRA-1-60, TRA-1-81, SSEA-4 – while being negative for the SSEA-1 marker. The stem cell lines form teratomas in scid-beige mice in 6-8 weeks and the teratomas contain tissues representative of all three germ layers. Transcriptional profiling of the lines by submitting global expression microarray data to a bioinformatic pluripotency assessment algorithm deemed all lines pluripotent and therefore, this approach is an attractive alternative to animal testing. The new iPSC lines can readily be used in downstream experiments involving the optimization of differentiation and tissue engineering.
The technology of induced pluripotent stem cells (iPSC) brings about potential cell replacement therapies, disease and developmental modeling, and drug and toxicological screening1,2,3. Replacement therapies can conceptually be achieved by cell injection, in-vitro differentiated tissue (such as cardiac patches) implantation, or guided regeneration by means of tissue engineering. Amniotic fluid (AFSC) and membrane stem cells (AMSC) are an excellent source of cells for these interventions either directly4,5,6,7 or as a starting cell population for reprogramming into pluripotency8,9,10,11,12.
Early approaches used undefined culture systems or reprogramming methods that require entail genomic integration of constructs9,10,11,12. A more recent study employed a xeno-free medium, even though a less defined basement membrane attachment matrix (BMM) was used, to generate iPSC from amniotic fluid epithelial cells. However, the teratoma formation assay was not included in the study along with a wealth of in-vitro and molecular data. Amniotic fluid epithelial cells were found to have a roughly 8-fold higher reprogramming efficiency when compared to neonatal fibroblasts13. In another study, mesenchymal stem cells from amniotic fluid were also found to be reprogrammed into iPSC with a much higher efficiency12.
Pluripotent stem cells can be differentiated into tissues representative of all 3 germ layers and thus have the broadest potential. Pediatric patients could benefit from the harvesting, reprogramming, and tissue engineering of their autologous amniotic fluid stem cells prenatally and amniotic membrane stem cells perinatally. Furthermore, the relatively low level of differentiation of fetal stem cells (lower than adult stem cells14,15) could theoretically aid in addressing the observed retention of epigenetic bias from source cells in iPSC16.
Here we present a protocol for reprogramming amniotic fluid and membrane stem cells to pluripotency in chemically defined xeno-free E8 medium on recombinant vitronectin17 (VTN) using episomal plasmids18. The main advantage of amniotic fluid and membrane cells as a source of cells for reprogramming lies in their availability pre- and perinatally and thus this approach would mainly benefit research into pediatric tissue engineering.
The protocol follows institutional guidelines of the ethics committee for human research. Written consent of the patient was obtained for using the amniotic fluid for research.
This protocol follows the policies of the Institutional Animal Care and Use Committee of the University of South Alabama.
1. Isolation and Culture of Primary Amniotic Mesenchymal Stem Cells
2. Reprogramming into Pluripotency
3. Characterization and Confirmation of Pluripotency
NOTE: Refer to the supplementary files for details on flow cytometry and confocal microscopy.
Informed written consent was obtained from patients before harvesting amniotic fluid for genetic testing purposes and dedicating a small aliquot of the fluid for research. No consent is required for the use of the amniotic membrane in research as the placenta represents medical waste. Amniotic fluid and membrane stem cells display typical mesenchymal properties, morphologically their cells are spindle-shaped and phase-bright. Upon reprogramming, the cells undergo mesenchymal-to-epithelial (MET) transition and acquire cobblestone-like morphology and spatial organization of the colonies, indicating epithelial properties. This process is initiated as early as 48-72 h following the introduction of reprogramming episomal plasmids. Absence of these colonies by day 5 of reprogramming would indicate failure of the experiment. The cells of the MET colonies proliferate and as a result, the colonies become compact, between day 5 and 14. Compact MET colonies are comprised of cells that are not easily individually discernible (Figure 1A). On around day 14, fully reprogrammed colonies appear with cells arranged in a monolayer, carrying prominent, easily discernible nuclei and nucleoli. They are ready to be mechanically isolated and expanded when the colonies reach a suitable size and become compact (Figure 1B).
Fully and partially reprogrammed colonies are present in the cultures throughout the entire reprogramming period, though partially reprogrammed colonies do not necessarily acquire full pluripotency. Figure 2 shows a representative flow cytometric analysis of embryonic stem cell (ESC) marker expression in fully and partially pluripotent colonies and their corresponding morphologies. Full pluripotency is associated with the expression of Oct4, Nanog, Sox2, TRA antigens and SSEA-4, while SSEA-1 expression is negative19,20,21 (Figure 2A). Partially pluripotent cells, however, do not express Nanog and TRA antigens20 (Figure 2B). The expression and localization of ESC markers should be confirmed by immunocytochemical staining and imaged using a wide-field or confocal microscope (Figure 3).
A functional confirmation of pluripotency is achieved by demonstrating the ability of the iPSC lines to form teratomas following subcutaneous injection of the cells into scid-beige mice. 6-8 weeks are needed for the teratomas to reach the end-point size. H&E staining of the tissues and examination by a pathologist is then performed to confirm the presence of tissues representative of all three germ layers – endoderm, neuroectoderm and mesoderm (Figure 4A). An alternative to animal testing is to analyze the transcriptional signature associated with pluripotency by genomic approaches like cDNA microarrays22,23. The proportion of the transcriptional profile that overlaps with one of a pool of well-established iPSC and ESC lines can then be quantified by the online bioinformatic pluripotency evaluation software in the form of a plot of two classifiers – pluripotency and novelty (Figure 4B). The higher the pluripotency score, the more the query iPSC line resembles the established lines. A high novelty score, however, could indicate deviations or even chromosomal aberrations, despite a high pluripotency score (such as in teratocarcinoma lines)22. All iPSC lines generated by following the protocol presented here have been deemed pluripotent by flow cytometry, imaging, teratoma formation, and transcriptional analysis methods.
Figure 1: Morphological progression of the cells during reprogramming. (A) The amniotic fluid and membrane stem cells, which represent source cells for reprogramming, display a typical mesenchymal morphology, elongated and phase-bright (left) until they undergo the mesenchymal-to-epithelial transition (MET) which leads to acquisition of epithelial properties and formation of colonies with cobble stone-like cells (center). These colonies proliferate and create irregular cellular masses of MET cells (right). (B) At the later stages of reprogramming (starting from around day 14), colonies of fully reprogrammed cells emerge – individually discernible cells with prominent nuclei and nucleoli arranged in monolayers, with well-defined borders (center) – and are present alongside MET colonies that are more numerous (left). A fully reprogrammed isolated mature clone is depicted on the right. Scale bar = 100 µm Please click here to view a larger version of this figure.
Figure 2: Flow cytometric analysis of the expression of ESC markers in fully and partially (MET) reprogrammed cell colonies. (A) The pluripotent expression profile is positive for Oct4, Nanog, Sox2, TRA-1-60, TRA-1-81 and SSEA-4, while negative for SSEA-1. (B) Partially pluripotent cell colonies – those that have undergone the MET but failed to progress to full pluripotency – are positive for Oct4 and Sox2 but Nanog, the TRA and SSEA antigens are absent. The associated morphologies are included for side-by-side comparison. Scale bars = 200 µm and 50 µm. Please click here to view a larger version of this figure.
Figure 3: Confocal imaging analysis of the expression of ESC markers in mature amniotic fluid iPSC. Transcription factors Oct3/4A, Nanog and Sox2 are localized in the nuclei while TRA and SSEA antigens are glycoproteins localized on the membrane. Scale bar = 50 µm. Images of greater magnification (Merge 2X) were included for Oct3/4, Nanog and Sox2 for better visualization of their nuclear localization. Scale bar = 25 µm. Transmitted – images acquired on transmitted light. Please click here to view a larger version of this figure.
Figure 4: Teratoma formation and transcriptional profiling in mature amniotic fluid and membrane iPSC. (A) Teratomas grown in scid-beige mice subcutaneously contain tissues representative of all three germ layers (100X magnification). (B) The global expression microarray profiles submitted to online pluripotency software returned a plot of two classifiers – pluripotency and novelty. High pluripotency scores and low novelty scores – red cloud – indicate an expression profile of a typical ESC/iPSC line. The blue cloud represents a cluster area for differentiated cells, while the faint blue cloud represents a cluster area for partially pluripotent cells. The amniotic fluid (3 lines) and membrane (4 lines) iPSC were deemed pluripotent by the test. An ESC line WA25 was included as a control and is identified here with a black arrow. Please click here to view a larger version of this figure.
The initial phase of iPSC generation from fetal stem cells entails the extraction of the source cells from the fetal tissues, their culture, expansion, and introduction of the episomal reprogramming plasmids. This phase is followed by a culture period of around 14-18 days before the first fully reprogrammed colonies can be expanded. The final phase is maturation of the iPSC clones. The initial extraction of amniotic membrane stem cells is achieved by means of a combined mechanical and enzymatic digestion of the amnion. We found that an incubation time of 30 min resulted in the highest number of cells extracted with the highest viability. The digestion procedure can produce small pieces of tissue and cell clumps. If the proportion of these relative to single cells is high, we recommend plating all clumps and single cells into one vessel since all can contribute to outgrowths of adherent cells. Plating amniotic fluid stem cells is straightforward as the cells are only mixed with the culture medium and incubated until colonies of adherent cells reach a sufficient size. Regular tissue culture-treated plasticware is perfectly suitable and we do not recommend specialty surfaces, even though they are intended for improved primary cell culture, since with these we observed lower viabilities and difficulties with the passaging process.
The amniotic fluid and membrane stem cells should be expanded and stocks frozen but, at the earliest convenience, the cells can be used as source cells for reprogramming. For the purpose of the introduction of the episomal plasmids into the cells, the transfection system used here with the transfection parameters set to 950 V, 40 ms, and 1 pulse has performed very well, with all lines attempted ultimately successfully reprogrammed (over 10 lines). The main competing delivery system operating on a similar principle did not produce a successful reprogramming experiment in our hands.
The transfected cells are seeded onto vitronectin-coated dishes in AFMC medium for the first 3-5 days, then the medium is switched to E8 supplemented with 100 µM sodium butyrate. This greatly increases the rate of full pluripotency acquisition. The first signs of morphological transformation can be seen as early as 48-72 h. The source cells undergo the MET and colonies of cells with epithelial morphology appear. These gradually proliferate and become compact. A subset of the colonies will acquire the morphological features of fully pluripotent stem cells – individually discernible cells with prominent nuclei and nucleoli, flat colonies with well-defined borders, as opposed to the fuzzy borders observed in partially pluripotent MET colonies. Upon the moment of the acquisition of full pluripotency, the compact MET cell colonies acquire prominent nuclei and the individual cells become discernible while creating a unique morphological pattern. To a trained eye, this pattern is a clear sign of successful reprogramming. However, to an investigator that lacks PSC culture training, identification of colonies that have successfully progressed to full pluripotency requires careful evaluation as MET and iPSC clones can be mistaken for each other. Figure 1 and Figure 2 provide examples of both. If MET clones are picked instead, thorough flow cytometry analysis will reveal the mistake, and in particular, the TRA-1-60 and TRA-1-81 antigens will most likely be absent as shown in Figure 2. Indeed, TRA antigens were previously found to be stringent pluripotency markers. However, partially pluripotent MET cells might be of interest in cancer research25.
This culture condition is suboptimal for the source AFSC/AMSC and eventually, their proliferation will slow down and they will acquire a flatter, fibroblast-like morphology. The source cells form tissues that can detach from the surface during the later stages of reprogramming, though this does not negatively affect the reprogramming process. On the contrary, the process sometimes leads to freeing up space for the reprogrammed colonies, while eliminating unwanted un-reprogrammed cellular material. Detached tissues can easily be discarded using a sterile pipette tip, leaving partially and fully pluripotent colonies behind, greatly simplifying manual selection downstream.
For manual picking of the fully reprogrammed colonies, we use an LCD imaging system, that can be placed in the safety cabinet, lacking any parts protruding out that would disturb the air flow. Other than this imaging system, no special equipment is needed as the picking itself can be performed using regular pipettes. The picked colonies are partially dissociated in EDTA/PBS solution before being plated into the target wells to grow out as clones. Depending on the line and the clone, for several passages, the cultures may be contaminated with spontaneously differentiating cells. Manual manipulation and serial passaging usually eliminate this problem. Clones riddled with extensive differentiation should be discarded, however, precious clones can be salvaged with various degrees of success by means of repeated manual picking of pluripotent colonies rather than disposing of differentiating cells. Episomal plasmids were shown to take around 15 passages to be lost completely from the iPSC26. Therefore, it is advisable to allow the clones to grow for at least that number of passages before using them for downstream applications and analyses, except for routine monitoring of TRA antigen expression and karyotype. TRA antigen expression can easily be monitored by flow cytometry as described here in the protocol, since the assay only requires around 200,000 cells, and can be performed whenever the researchers are in doubt as to whether the cultured clones are maintaining pluripotency properly. Flow cytometry analysis of the ESC marker expression is not considered to be sufficient to confirm pluripotency in candidate lines19.
Teratoma formation assay is the standard conclusive pluripotency test27. PSC grown in chemically defined, xeno-free conditions are particularly susceptible to dissociation-induced death and hence, injecting them subcutaneously as clumps is necessary for their successful implantation8,28. Following injection, usually 4-6 weeks are enough for the growth of the xeno-grafts to be visible and before week 8, all can be harvested, H&E-stained and analyzed. Animal welfare, cost, and long testing periods needed are reasons for developing alternative methods. Genomic analyses combined with advanced, machine learning-powered bioinformatic approaches can provide an accurate evaluation of global expression profiles. The cost of obtaining such data is comparable to the cost of the teratoma formation assay, however, the genomic approach is considerably faster and no animals have to be used. One such assay is a bioinformatic pluripotency evaluation software22. It is implemented as an online interface (Table of Materials). The growing popularity and plummeting cost of RNA sequencing will ensure continuity of this approach. An alternative to this pluripotency software is available from Johns Hopkins University23 (cellnet.hms.harvard.edu) and is based on a similar approach and is able to accept microarray data to analyze the transcriptome of human samples. The advantage of this software is that it has the ability to identify not only pluripotent stem cells but also differentiated cells and, since its curated datasets were derived from primary tissues, the level of similarity between in-vitro grown cells/tissues and in-vivo tissues can be determined, providing an excellent quality control for the development of differentiation protocols or tissue engineering. The test has the capacity to classify the queries into 20 different cell or tissue types. At present, it requires microarray data but the authors are working towards expanding the platform options to RNA sequencing as well.
By following the presented protocol, researchers can generate iPSC lines from amniotic fluid and membrane stem cells with a very high reproducibility in fully chemically defined and xeno-free medium and using a non-integrating reprogramming method. These lines can be used in basic research to optimize differentiation protocols and ultimately in disease modeling, drug screening, or pediatric tissue engineering studies.
The authors have nothing to disclose.
This work was supported by the Fonds Medizinische Forschung at the University of Zurich, Forschungskredit of the University of Zurich, The SCIEX NMSCh under Fellowships 10.216 and 12.176, The Swiss Society of Cardiology, The Swiss National Science Foundation under Grant [320030-122273] and [310030-143992], The 7th Framework Programme, Life Valve, European Commission under Grant [242008], the Olga Mayenfisch Foundation, the EMDO Foundation, the Start-up Grant 2012 of the University Hospital Zurich, and internal funding of the Mitchell Cancer Institute.
Tumor Dissociation Kit, human | Miltenyi Biotec | 130-095-929 | tissue dissociation system, reagent kit, includes tissue dissociation tubes and tissue dissociation enzymes |
gentleMACS Dissociator | Miltenyi Biotec | 130-093-235 | tissue dissociation system, dissociator |
Thermo Scientific™ Shandon™ Disposable Scalpel No. 10, Sterile, Individually Wrapped, 5.75 (14.6cm) | Thermo-Fisher | 3120032 | |
70 µm cell strainers | Corning | 10054-456 | |
RPMI 1640 medium | Thermo-Fisher | 32404014 | |
rocking platform | VWR | 40000-300 | |
50 ml centrifuge tubes | Thermo-Fisher | 339652 | |
15 ml centrifuge tubes | Thermo-Fisher | 339650 | |
EBM-2 basal medium | Lonza | CC-3156 | basal medium for AFMC medium |
FGF 2 Human (expressed in E. coli, non-glycosylated) | Prospec Bio | CYT-218 | bFGF, supplement for AFMC medium |
EGF Human, Pichia | Prospec Bio | CYT-332 | EGF, supplement for AFMC medium |
LR3 Insulin Like Growth Factor-1 Human Recombinant | Prospec Bio | CYT-022 | IGF, supplement for AFMC medium |
Fetal Bovine Serum, embryonic stem cell-qualified | Thermo-Fisher | 10439024 | FBS |
Antibiotic-Antimycotic (100X) | Thermo-Fisher | 15240062 | for primary AFSC/AMSC, for routine AFSC/AMSC it should not be necessary, do not use in medium for transfected cells! |
Accutase cell detachment solution | StemCell Technologies | 07920 | cell detachment enzyme |
CryoStor™ CS10 | StemCell Technologies | 07930 | complete freezing medium |
PBS, pH 7.4 | Thermo-Fisher Scientific | 10010023 | |
EndoFree Plasmid Maxi Kit (10) | Qiagen | 12362 | for plasmid isolation |
pEP4 E02S EN2K | Addgene | 20925 | EN2K, reprogramming factors Oct4+Sox2, Nanog+Klf4 |
pEP4 E02S ET2K | Addgene | 20927 | ET2K, reprogramming factors Oct4+Sox2, SV40LT+Klf4 |
pCEP4-M2L | Addgene | 20926 | M2L, reprogramming factors c-Myc+LIN28 |
NanoDrop 2000c UV-Vis Spectrophotometer | Thermo-Fisher | ND-2000C | spectrophotometer |
Neon® Transfection System | Thermo-Fisher | MPK5000 | transfection system, components: Neon pipette – transfection pipette Neon device – transfection device |
Neon® Transfection System 10 µL Kit | Thermo-Fisher | MPK1025 | consumables kit for the Neon Transfection System, it contains: Neon tip – transfection tip Neon tube – transfection tube buffer R – resuspension buffer buffer E – electrolytic buffer |
Stemolecule™ Sodium Butyrate | StemGent | 04-0005 | small molecule enhancer of reprogramming |
TeSR-E8 | StemCell Technologies | 05940 | E8 medium |
Vitronectin XF™ | StemCell Technologies | 07180 | VTN, stock concentration 250 µg/ml, used for coating at 1 µg/cm2 in vitronectin dilution (CellAdhere) buffer |
CellAdhere™ Dilution Buffer | StemCell Technologies | 07183 | vitronectin dilution buffer |
UltraPure™ 0.5M EDTA, pH 8.0 | Thermo-Fisher | 15575020 | dilute with PBS to 0.5 mM before use |
EVOS® FL Imaging System | Thermo-Fisher Scientific | AMF4300 | LCD imaging microscope system |
CKX53 Inverted Microscope | Olympus | phase contrast cell culture microscope | |
Pierce™ 16% Formaldehyde (w/v), Methanol-free | Thermo-Fisher | 28908 | dilute to 4% with PBS before use, diluted can be stored at 2-8 °C for 1 week |
Perm Buffer III | BD Biosciences | 558050 | permeabilization buffer, chill to -20 °C before use |
Mouse IgG1, κ Isotype Control, Alexa Fluor® 488 | BD Biosciences | 557782 | isotype control for Oct3/4A, Nanog |
Mouse IgG1, κ Isotype Control, Alexa Fluor® 647 | BD Biosciences | 557783 | isotype control for Sox2 |
Mouse anti-human Oct3/4 (Human Isoform A), Alexa Fluor® 488 | BD Biosciences | 561628 | |
Mouse anti-human Nanog, Alexa Fluor® 488 | BD Biosciences | 560791 | |
Mouse anti-human Sox-2, Alexa Fluor® 647 | BD Biosciences | 562139 | |
Mouse IgGM, κ Isotype Control, Alexa Fluor® 488 | BD Biosciences | 401617 | isotype control for TRA-1-60 |
Mouse IgGM, κ Isotype Control, Alexa Fluor® 647 | BD Biosciences | 401618 | isotype control for TRA-1-81 |
Mouse anti-human TRA-1-60, Alexa Fluor® 488 | BD Biosciences | 330613 | |
Mouse anti-human TRA-1-81, Alexa Fluor® 647 | BD Biosciences | 330705 | |
Mouse IgG1, κ Isotype Control, Alexa Fluor® 488 | BD Biosciences | 400129 | isotype control for SSEA-1 |
Mouse IgG3, κ Isotype Control, Alexa Fluor® 647 | BD Biosciences | 401321 | isotype control for SSEA-4 |
Mouse anti-human SSEA-1, Alexa Fluor® 488 | BD Biosciences | 323010 | |
Mouse anti-human SSEA-4, Alexa Fluor® 647 | BD Biosciences | 330407 | |
Affinipure F(ab')2 Fragment Goat Anti-Mouse IgG+IgM, Alexa Fluor® 488 | Jackson Immunoresearch | 115-606-068 | use at a dilution of 1:600 or further optimize |
Affinipure F(ab')2 Fragment Goat Anti-Mouse IgG+IgM, Alexa Fluor® 647 | Jackson Immunoresearch | 115-546-068 | use at a dilution of 1:600 or further optimize |
DAPI | Thermo-Fisher Scientific | D21490 | stock solution 10 mM, further dilute to 1:12.000 for a working solution |
Corning® Matrigel® Growth Factor Reduced, Phenol Red-Free | Corning | 356231 | basement membrane matrix (BMM) |
scid-beige mice, female | Taconic | CBSCBG-F | |
RNeasy Plus Mini Kit (50) | Qiagen | 74134 | RNA isolation kit |
T-25 flasks, tissue culture-treated | Thermo-Fisher | 156367 | |
T-75 flasks, tissue culture-treated | Thermo-Fisher | 156499 | |
Nunc™ tissue-culture dish | Thermo-Fisher | 12-567-650 | 10 cm tissue culture dish |
6-well plates, tissue-culture treated | Thermo-Fisher | 140675 | |
Neubauer counting chamber (hemacytometer) | VWR | 15170-173 | |
Mr. Frosty™ Freezing Container | Thermo-Fisher | 5100-0001 | freezing container |
FACS tubes, Round Bottom Polystyrene Test Tube, 5ml | Corning | 352058 | 5 ml polystyrene tubes |
Eppendorf tubes, 1.5 ml | Thermo-Fisher | 05-402-96 | 1.5 ml microcentrifuge tubes |
PCR tubes, 200 µl | Thermo-Fisher | 14-222-262 | |
pipette tips, 100 to 1250 µl | Thermo-Fisher | 02-707-407 | narrow-bore 1 mL tips |
pipette tips, 5 to 300 µl | Thermo-Fisher | 02-707-410 | |
pipette tips, 0.1 to 10 µl | Thermo-Fisher | 02-707-437 | |
wide-bore pipette tips, 1000 µl | VWR | 89049-166 | wide-bore 1 mL tips |
glass Pasteur pipettes | Thermo-Fisher | 13-678-20A | |
ethanol, 200 proof | Thermo-Fisher | 04-355-451 | |
vortex mixer | VWR | 10153-842 | |
chambered coverglass, 8-well, 1.5mm borosilicate glass | Thermo-Fisher | 155409 | glass-bottom confocal-grade cultureware |
22G needles | VWR | 82002-366 | |
insulin syringes | Thermo-Fisher | 22-253-260 | |
Formalin solution, neutral buffered, 10% | Sigma-Aldrich | HT501128-4L | fixation of explanted teratomas |
Illumina HT-12 v4 Expression BeachChip | Illumina | BD-103-0204 | expression microarray, supported by PluriTest, discontinued by manufacturer |
PrimeView Human Genome U219 Array Plate | Thermo-Fisher | 901605 | expression microarray (formerly Affymetrix brand), soon to be supported by PluriTest |
GeneChip™ Human Genome U133 Plus 2.0 Array | Thermo-Fisher | 902482 | expression microarray (formerly Affymetrix brand), supported by CellNet, soon to be supported by PluriTest |
PluriTest® | Coriell Institute | www.pluritest.org, free service for bioinformatic assessment of pluripotency, accepts microarray data – *.idat files from HT-12 v4 platform, soon to support U133, U219 microarray and RNA sequencing data | |
CellNet | Johns Hopkins Üniversitesi | cellnet.hms.harvard.edu, free service for bioinformatic identification of cell type, including plutipotent stem cells, based on U133 microarray data – *.cel files, soon to support RNA sequencing data |